Person · CIK 1650131
Peter Radovich
Director at MBX Biosciences; PRESIDENT AND COO at Mirum Pharmaceuticals
Earlier: Rain Oncology and Global Blood Therapeutics
Sold on Form 4$7.1M
Noticed on Form 144$2.8M
Bought on Form 4$250K
Companies4
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| MBX Biosciences MBX | Stock option (right to buy) exercise $53.50, expires Oct 20, 2036, into Common Stock | Directly | 18,200 | Oct 20, 2026 · Filing · EDGAR |
| Mirum Pharmaceuticals MIRM | Common Stock | Directly | 57,260 | Jun 5, 2026 · Filing · EDGAR |
| Mirum Pharmaceuticals MIRM | Stock Option (right to buy) exercise $19.19, expires Jan 6, 2031, into Common Stock | Directly | 48,012 | Jun 5, 2026 · Filing · EDGAR |
| Rain Oncology | Common Stock | By Trust | 8,796 | Apr 27, 2021 · Filing · EDGAR |
| Global Blood Therapeutics | Common Stock | Directly | 8,833 | Feb 14, 2018 · Filing · EDGAR |
| Global Blood Therapeutics | Restricted Stock Units into Common Stock | Directly | 5,600 | Feb 14, 2018 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) | Bought (Form 4) |
|---|---|---|---|
| Q1 2026 | $2.3M | $2.1M | — |
| Q1 2025 | $1.4M | $676K | — |
| Q1 2024 | $197K | — | — |
| Q3 2023 | $37K | — | — |
| Q1 2023 | $28K | Not machine-readable | — |
| Q4 2021 | $26K | Not machine-readable | — |
| Q1 2018 | $2.6M | Not machine-readable | — |
| Q4 2017 | $438K | Not machine-readable | — |
| Q3 2017 | $72K | Not machine-readable | — |
| Q3 2015 | — | — | $250K |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jan 31, 2023 · 2 notices | ||||
| Mar 17, 2026 | 16,515 · ~$1.5M | Mar 16, 2026 | Sold as noticed Sold 16,515 at $91.98 on Mar 16 · $1.5M Form 4 | Filing · EDGAR |
| Feb 2, 2026 | 2,631 · ~$273K | Feb 2, 2026 | Sold as noticed Sold 2,631 at $103.30 on Feb 2 · $272K Form 4 | Filing · EDGAR |
| Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jan 23, 2024 · 1 notice | ||||
| Jan 28, 2026 | 3,143 · ~$305K | Jan 26, 2026 | Partly sold Sold 2,382 at $93.33 on Jan 22 · $222K likely match Form 4 | Filing · EDGAR |
| Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice | ||||
| Mar 4, 2025 | 14,850 · ~$676K | Mar 4, 2025 | Sold as noticed Sold 14,850 in 2 sales, Mar 4 to Mar 4 · $677K Form 4 | Filing · EDGAR |
| Sales without a matching Form 144 · 16 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 3,143 at $96.19 on Jan 26, 2026 · $302K | Filing · EDGAR |
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 7,879 at $44.21 on Mar 17, 2025 · $348K | Filing · EDGAR |
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 2,627 at $48.22 on Feb 3, 2025 · $127K | Filing · EDGAR |
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 3,177 at $47.92 on Jan 24, 2025 · $152K | Filing · EDGAR |
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 1,998 at $42.82 on Jan 7, 2025 · $86K | Filing · EDGAR |
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 4,303 at $25.80 on Mar 25, 2024 · $111K | Filing · EDGAR |
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 1,790 at $26.19 on Feb 2, 2024 · $47K | Filing · EDGAR |
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 1,408 at $28.03 on Jan 8, 2024 · $39K | Filing · EDGAR |
| — | — | — | Sold without notice Mirum Pharmaceuticals (MIRM): Sold 1,425 at $25.65 on Jul 3, 2023 · $37K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Mirum Pharmaceuticals (MIRM): Sold 1,379 at $20.62 on Jan 9, 2023 · $28K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Mirum Pharmaceuticals (MIRM): Sold 1,364 at $19.26 on Oct 1, 2021 · $26K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 812 at $57.30 on Feb 1, 2018 · $47K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 30,000 at $60.00 on Jan 23, 2018 · $1.8M (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 15,000 at $50.00 on Jan 10, 2018 · $750K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 12,500 at $35.00 on Oct 30, 2017 · $438K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Global Blood Therapeutics: Sold 2,410 at $30.00 on Aug 31, 2017 · $72K (10b5-1 plan) | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
Mirum Pharmaceuticals MIRM President and COO · filings 2020 to 2026 · sold $4M · $2.8M noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Option or RSU exercised or converted | +16,988 | $19.19 | $326K | 57,260 direct | Filing · EDGAR |
| Jun 5, 2026 | Option or RSU exercised or converted Stock Option (right to buy) | −16,988 | 48,012 direct | Filing · EDGAR | ||
| Mar 16, 2026 | Open-market or private sale | −16,515 | $91.98 | $1.5M | 40,272 direct | Filing · EDGAR |
| Mar 15, 2026 | Option or RSU exercised or converted | +7,220 | 33,787 direct | Filing · EDGAR | ||
| Mar 15, 2026 | Option or RSU exercised or converted | +23,000 | 56,787 direct | Filing · EDGAR | ||
| Mar 15, 2026 | Option or RSU exercised or converted Performance Restricted Stock Units | −7,220 | 0 direct | Filing · EDGAR | ||
| Mar 15, 2026 | Option or RSU exercised or converted Performance Restricted Stock Units | −23,000 | 11,500 direct | Filing · EDGAR | ||
| Mar 6, 2026 | Option or RSU exercised or converted | +5,912 | $15.87 | $94K | 26,567 direct | Filing · EDGAR |
| Mar 6, 2026 | Option or RSU exercised or converted Stock Option (right to buy) | −5,912 | 54,088 direct | Filing · EDGAR | ||
| Feb 2, 2026 | Open-market or private sale | −2,631 | $103.30 | $272K | 20,655 direct | Filing · EDGAR |
| Jan 28, 2026 | Grant or award from the company Stock Option (right to buy) | +25,120 | 25,120 direct | Filing · EDGAR | ||
| Jan 28, 2026 | Grant or award from the company Restricted Stock Units | +16,280 | 16,280 direct | Filing · EDGAR | ||
| Jan 28, 2026 | Grant or award from the company Performance Restricted Stock Units | +34,500 | 34,500 direct | Filing · EDGAR | ||
| Jan 26, 2026 | Open-market or private sale | −3,143 | $96.19 | $302K | 23,286 direct | Filing · EDGAR |
| Jan 23, 2026 | Option or RSU exercised or converted | +5,750 | 26,429 direct | Filing · EDGAR | ||
| Jan 23, 2026 | Option or RSU exercised or converted Restricted Stock Units | −5,750 | 5,750 direct | Filing · EDGAR | ||
| Jan 22, 2026 | Open-market or private sale | −2,382 | $93.33 | $222K | 20,679 direct | Filing · EDGAR |
| Jan 21, 2026 | Option or RSU exercised or converted | +4,167 | 23,061 direct | Filing · EDGAR | ||
| Jan 21, 2026 | Option or RSU exercised or converted Restricted Stock Units | −4,167 | 8,333 direct | Filing · EDGAR | ||
| Mar 17, 2025 | Open-market or private sale | −7,879 | $44.21 | $348K | 18,672 direct | Filing · EDGAR |
| Mar 15, 2025 | Option or RSU exercised or converted | +14,440 | 26,551 direct | Filing · EDGAR | ||
| Mar 15, 2025 | Option or RSU exercised or converted Performance Restricted Stock Units | −14,440 | 7,220 direct | Filing · EDGAR | ||
| Mar 4, 2025 | Open-market or private sale | −13,681 | $45.57 | $623K | 13,280 direct | Filing · EDGAR |
| Mar 4, 2025 | Open-market or private sale | −1,169 | $45.74 | $53K | 12,111 direct | Filing · EDGAR |
| Feb 3, 2025 | Open-market or private sale | −2,627 | $48.22 | $127K | 26,961 direct | Filing · EDGAR |
| Jan 24, 2025 | Open-market or private sale | −3,177 | $47.92 | $152K | 29,588 direct | Filing · EDGAR |
| Jan 23, 2025 | Option or RSU exercised or converted | +5,750 | 32,765 direct | Filing · EDGAR | ||
| Jan 23, 2025 | Option or RSU exercised or converted Restricted Stock Units | −5,750 | 11,500 direct | Filing · EDGAR | ||
| Jan 21, 2025 | Grant or award from the company Stock Option (right to buy) | +50,000 | 50,000 direct | Filing · EDGAR | ||
| Jan 21, 2025 | Grant or award from the company Restricted Stock Units | +12,500 | 12,500 direct | Filing · EDGAR | ||
| Jan 21, 2025 | Grant or award from the company Performance Restricted Stock Units | +21,660 | 21,660 direct | Filing · EDGAR | ||
| Jan 7, 2025 | Open-market or private sale | −1,998 | $42.82 | $86K | 27,015 direct | Filing · EDGAR |
| Mar 25, 2024 | Open-market or private sale | −4,303 | $25.80 | $111K | 29,013 direct | Filing · EDGAR |
| Feb 2, 2024 | Open-market or private sale | −1,790 | $26.19 | $47K | 34,695 direct | Filing · EDGAR |
| Jan 23, 2024 | Grant or award from the company Stock Option (right to buy) | +70,000 | 70,000 direct | Filing · EDGAR | ||
| Jan 23, 2024 | Grant or award from the company Restricted Stock Units | +17,250 | 17,250 direct | Filing · EDGAR | ||
| Jan 8, 2024 | Open-market or private sale | −1,408 | $28.03 | $39K | 36,485 direct | Filing · EDGAR |
| Nov 10, 2023 | Grant or award from the company | +218 | $22.29 | $5K | 37,893 direct | Filing · EDGAR |
| Jul 3, 2023 | Open-market or private sale | −1,425 | $25.65 | $37K | 37,675 direct | Filing · EDGAR |
| May 10, 2023 | Grant or award from the company | +968 | $16.92 | $16K | 39,100 direct | Filing · EDGAR |
| Jan 31, 2023 | Grant or award from the company | +14,440 | 38,132 direct | Filing · EDGAR | ||
| Jan 31, 2023 | Grant or award from the company Stock Option (right to buy) | +57,750 | 57,750 direct | Filing · EDGAR | ||
| Jan 9, 2023 | Open-market or private sale | −1,379 | $20.62 | $28K | 33,316 direct | Filing · EDGAR |
| Nov 10, 2022 | Grant or award from the company | +292 | $17.05 | $5K | 23,692 direct | Filing · EDGAR |
| May 10, 2022 | Grant or award from the company | +1,169 | $13.57 | $16K | 23,400 direct | Filing · EDGAR |
| Jan 6, 2022 | Grant or award from the company | +10,000 | 22,231 direct | Filing · EDGAR | ||
| Jan 6, 2022 | Grant or award from the company Stock Option (right to buy) | +60,000 | 60,000 direct | Filing · EDGAR | ||
| Nov 10, 2021 | Grant or award from the company | +958 | $13.52 | $13K | 12,231 direct | Filing · EDGAR |
| Oct 1, 2021 | Open-market or private sale | −1,364 | $19.26 | $26K | 11,273 direct | Filing · EDGAR |
| Sep 29, 2021 | Grant or award from the company | +8,125 | 12,637 direct | Filing · EDGAR | ||
| May 10, 2021 | Grant or award from the company | +1,006 | $14.62 | $15K | 4,512 direct | Filing · EDGAR |
| Jan 7, 2021 | Grant or award from the company Stock Option (right to buy) | +65,000 | 65,000 direct | Filing · EDGAR | ||
| Nov 10, 2020 | Grant or award from the company | +861 | $15.27 | $13K | 3,506 direct | Filing · EDGAR |
| Apr 28, 2020 | Grant or award from the company Stock Option (right to buy) | +185,000 | 185,000 direct | Filing · EDGAR |
Rain Oncology Director · filings 2021 to 2024
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Jan 26, 2024 | Tendered in a change of control | −8,796 | 0 direct | Filing · EDGAR | ||
| Jan 26, 2024 | Returned to the company Stock Option (Right to Buy) | −13,890 | 0 direct | Filing · EDGAR | ||
| Jan 26, 2024 | Returned to the company Stock Option (Right to Buy) | −42,596 | 0 direct | Filing · EDGAR | ||
| Jan 26, 2024 | Returned to the company Stock Option (Right to Buy) | −35,000 | 0 direct | Filing · EDGAR | ||
| Jan 26, 2024 | Returned to the company Stock Option (Right to Buy) | −20,000 | 0 direct | Filing · EDGAR | ||
| Aug 9, 2023 | Grant or award from the company Stock Option (Right to Buy) | +35,000 | 35,000 direct | Filing · EDGAR | ||
| Jun 1, 2022 | Grant or award from the company Stock Option (Right to Buy) | +20,000 | 20,000 direct | Filing · EDGAR | ||
| Apr 27, 2021 | Derivative converted | +8,796 | 8,796 By Trust | Filing · EDGAR | ||
| Apr 27, 2021 | Derivative converted Series A Preferred Stock | −9,500 | 0 By Trust | Filing · EDGAR |
Global Blood Therapeutics Senior VP, Operations · filings 2015 to 2018 · sold $3.1M · bought $250K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Feb 14, 2018 | Option or RSU exercised or converted | +1,600 | 9,627 direct | Filing · EDGAR | ||
| Feb 14, 2018 | Shares withheld for tax or exercise price | −794 | $62.30 | $49K | 8,833 direct | Filing · EDGAR |
| Feb 14, 2018 | Option or RSU exercised or converted Restricted Stock Units | −1,600 | 5,600 direct | Filing · EDGAR | ||
| Feb 1, 2018 | Option or RSU exercised or converted | +3,000 | 8,667 direct | Filing · EDGAR | ||
| Feb 1, 2018 | Shares withheld for tax or exercise price | −1,038 | $59.60 | $62K | 7,629 direct | Filing · EDGAR |
| Feb 1, 2018 | Sale under a 10b5-1 plan | −812 | $57.30 | $47K | 6,817 direct | Filing · EDGAR |
| Feb 1, 2018 | Option or RSU exercised or converted Restricted Stock Units | −3,000 | 18,000 direct | Filing · EDGAR | ||
| Feb 1, 2018 | Grant or award from the company Stock Option (Right to Buy) | +26,500 | 26,500 direct | Filing · EDGAR | ||
| Feb 1, 2018 | Grant or award from the company Restricted Stock Units | +17,000 | 17,000 direct | Filing · EDGAR | ||
| Jan 31, 2018 | Option or RSU exercised or converted | +1,600 | 6,221 direct | Filing · EDGAR | ||
| Jan 31, 2018 | Shares withheld for tax or exercise price | −554 | $57.90 | $32K | 5,667 direct | Filing · EDGAR |
| Jan 31, 2018 | Option or RSU exercised or converted Restricted Stock Units | −1,600 | 7,200 direct | Filing · EDGAR | ||
| Jan 24, 2018 | Option or RSU exercised or converted | +1,600 | 5,181 direct | Filing · EDGAR | ||
| Jan 24, 2018 | Shares withheld for tax or exercise price | −560 | $58.15 | $33K | 4,621 direct | Filing · EDGAR |
| Jan 24, 2018 | Option or RSU exercised or converted Restricted Stock Units | −1,600 | 8,800 direct | Filing · EDGAR | ||
| Jan 23, 2018 | Option or RSU exercised or converted | +30,000 | $1.61 | $48K | 33,581 direct | Filing · EDGAR |
| Jan 23, 2018 | Sale under a 10b5-1 plan | −30,000 | $60.00 | $1.8M | 3,581 direct | Filing · EDGAR |
| Jan 23, 2018 | Option or RSU exercised or converted Employee Stock Option (Right to Buy) | −30,000 | 35,000 direct | Filing · EDGAR | ||
| Jan 16, 2018 | Option or RSU exercised or converted | +1,600 | 4,284 direct | Filing · EDGAR | ||
| Jan 16, 2018 | Shares withheld for tax or exercise price | −703 | $52.10 | $37K | 3,581 direct | Filing · EDGAR |
| Jan 16, 2018 | Option or RSU exercised or converted Restricted Stock Units | −1,600 | 10,400 direct | Filing · EDGAR | ||
| Jan 10, 2018 | Option or RSU exercised or converted | +15,000 | $1.61 | $24K | 17,684 direct | Filing · EDGAR |
| Jan 10, 2018 | Sale under a 10b5-1 plan | −15,000 | $50.00 | $750K | 2,684 direct | Filing · EDGAR |
| Jan 10, 2018 | Option or RSU exercised or converted Employee Stock Option (Right to Buy) | −15,000 | 65,000 direct | Filing · EDGAR | ||
| Oct 30, 2017 | Sale under a 10b5-1 plan | −12,500 | $35.00 | $438K | 0 By Trust | Filing · EDGAR |
| Aug 31, 2017 | Sale under a 10b5-1 plan | −2,410 | $30.00 | $72K | 2,684 direct | Filing · EDGAR |
| Aug 11, 2017 | Grant or award from the company Restricted Stock Units | +12,000 | 12,000 direct | Filing · EDGAR | ||
| Aug 1, 2017 | Option or RSU exercised or converted | +3,000 | 6,222 direct | Filing · EDGAR | ||
| Aug 1, 2017 | Shares withheld for tax or exercise price | −1,128 | $25.10 | $28K | 5,094 direct | Filing · EDGAR |
| Aug 1, 2017 | Option or RSU exercised or converted Restricted Stock Units | −3,000 | 21,000 direct | Filing · EDGAR | ||
| Jul 31, 2017 | Grant or award from the company | +661 | $13.69 | $9K | 3,345 direct | Filing · EDGAR |
| Jan 31, 2017 | Grant or award from the company | +812 | $13.73 | $11K | 3,222 direct | Filing · EDGAR |
| Jan 17, 2017 | Grant or award from the company Restricted Stock Units | +24,000 | 24,000 direct | Filing · EDGAR | ||
| Jan 17, 2017 | Grant or award from the company Stock Option (right to buy) | +36,000 | 36,000 direct | Filing · EDGAR | ||
| Sep 29, 2016 | Grant or award from the company Employee Stock Option (Right to Buy) | +7,500 | 7,500 direct | Filing · EDGAR | ||
| Sep 8, 2016 | Grant or award from the company Employee Stock Option (Right to Buy) | +25,000 | 25,000 direct | Filing · EDGAR | ||
| Jul 31, 2016 | Grant or award from the company | +1,185 | $15.20 | $18K | 2,410 direct | Filing · EDGAR |
| Mar 10, 2016 | Grant or award from the company Employee Stock Option (Right to Buy) | +7,500 | 7,500 direct | Filing · EDGAR | ||
| Feb 1, 2016 | Grant or award from the company | +1,225 | $16.09 | $20K | 13,725 direct | Filing · EDGAR |
| Aug 17, 2015 | Open-market or private purchase | +12,500 | $20.00 | $250K | 12,500 direct | Filing · EDGAR |
All 62 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 22, 2026 | Form 4 | MBX Biosciences MBX | Filing · EDGAR |
| Oct 22, 2026 | Form 3 | MBX Biosciences MBX | Filing · EDGAR |
| Jun 8, 2026 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Mar 17, 2026 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Mar 17, 2026 | Form 144 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Mar 11, 2026 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Feb 3, 2026 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Feb 2, 2026 | Form 144 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 30, 2026 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 28, 2026 | Form 144 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 27, 2026 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 23, 2026 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Mar 18, 2025 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Mar 5, 2025 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Mar 4, 2025 | Form 144 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Feb 4, 2025 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 27, 2025 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 23, 2025 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 8, 2025 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Mar 25, 2024 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Mar 18, 2024 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Feb 5, 2024 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 26, 2024 | Form 4 | Rain Oncology | Filing · EDGAR |
| Jan 25, 2024 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 9, 2024 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Nov 15, 2023 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Aug 11, 2023 | Form 4 | Rain Oncology | Filing · EDGAR |
| Jul 5, 2023 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| May 19, 2023 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Feb 2, 2023 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Nov 14, 2022 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Aug 19, 2022 | Form 4 | Rain Oncology | Filing · EDGAR |
| May 12, 2022 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Jan 7, 2022 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Nov 15, 2021 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Oct 1, 2021 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| May 12, 2021 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Apr 27, 2021 | Form 4 | Rain Oncology | Filing · EDGAR |
| Apr 22, 2021 | Form 3 | Rain Oncology | Filing · EDGAR |
| Jan 11, 2021 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Nov 12, 2020 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Apr 30, 2020 | Form 4 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Apr 30, 2020 | Form 3 | Mirum Pharmaceuticals MIRM | Filing · EDGAR |
| Feb 16, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 14, 2018 | Form 5 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 2, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 26, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 25, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 18, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 11, 2018 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Oct 31, 2017 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Sep 5, 2017 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Aug 14, 2017 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Aug 3, 2017 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 14, 2017 | Form 5 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 19, 2017 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Oct 3, 2016 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Sep 12, 2016 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Mar 14, 2016 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Feb 3, 2016 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Jan 7, 2016 | Form 4 | Global Blood Therapeutics | Filing · EDGAR |
| Aug 11, 2015 | Form 3 | Global Blood Therapeutics | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.